

IN THE CLAIMS:

The following claim listing will replace all previous listings of the claims:

1. (Currently amended) A method for ~~modulating~~ inhibiting or otherwise down-regulating immuno-activity of a cell selected from a stimulator myeloid dendritic cell (DC) and a responder CD4⁺CD8⁻ T cell or CD4⁺CD8⁺ T cell said method comprising contacting said cell with an effective amount of an antibody or antigen-binding fragment thereof which couples, binds or otherwise associates with CD83 and in turn ~~prevents~~, inhibits or otherwise down-regulates one or more functional activities of said cell by inducing cell lysis.
2. (Currently amended) The method of claim 1 wherein the antibody is a monoclonal antibody ~~or a functional equivalent thereof~~.
3. (Original) The method of claim 1 wherein the cell is mammalian derived.
4. (Original) The method of claim 3 wherein the mammalian cell is a human cell.
5. (Canceled)
6. (Original) The method of claim 1 wherein lysis is caused by antibody-dependent cell-mediated cytotoxicity.
7. (Currently amended) The method of claim 2 wherein the antibody is conjugated with a toxic component which induces or otherwise facilitates lysis of ~~the APC and/or lymphocyte~~ said cell.
8. (Currently amended) A method for ~~modulating~~ inhibiting or otherwise down-regulating the immuno-activity of a myeloid DC and/or T cell, said method comprising contacting said DC and/or T cell with an effective amount of a monoclonal antibody specific for CD83 for a time and under conditions sufficient to ~~prevent~~, inhibit or otherwise down-regulate one or more of antigen endocytosis, antigen processing and/or antigen presentation by said DC and activation of

macrophages, stimulation of antibody production, and/or killing of target cells by said T cell.

9. (Currently amended) A method for ~~modulating~~ inhibiting or otherwise down-regulating an immune response in a subject, said method comprising administering to said subject an effective amount of an antibody which couples, binds or otherwise associates with a myeloid DC's and/or T cell's surface activation molecule for a time and under conditions sufficient to induce cell lysis of said DC and/or T cell.

10. (Currently amended) A method for down-regulating the immuno-activity of an immuno-competent graft in a subject, said method comprising administering to said subject an effective amount of an antibody which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's CD83 molecule, for a time and under conditions sufficient to induce cell lysis of said DC and/or a T cell.

11. (Currently amended) A method for down-regulating the immuno-activity of a bone marrow graft in a subject, said method comprising administering to said subject an effective amount of monoclonal antibody against CD83, for a time and under conditions sufficient to ~~prevent~~, inhibit or otherwise down-regulate one or more functional activities of a DC and/or T-cell by inducing cell lysis.

12. (Currently amended) A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft in a subject, said method comprising contacting said graft with an effective amount of an antibody or a ~~derivative, homolog, analog, chemical equivalent or mimetic~~ an antigen-binding fragment thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's surface activation CD83 molecule, for a time and under conditions sufficient to ~~prevent~~, inhibit or otherwise down-regulate the immuno-activity of said DC and/or T cell by inducing cell lysis.

13. (Currently amended) The method of claim ~~[[17]]~~12 wherein the immuno-competent

graft comprises allogenic bone marrow cells.

14. (Currently amended) The method of claim 12 wherein ~~the lymphocyte~~said T cell is a $CD4^+CD8^-$ or $CD4^-CD8^+$ T cell.

15. (Currently amended) A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft in a subject, said method comprising contacting said graft with an effective amount of an antibody or ~~a derivative, homolog, analog, chemical equivalent or mimetic~~ an antigen-binding fragment thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's CD83 molecule derived from said graft, for a time and under conditions sufficient to ~~prevent~~, inhibit or otherwise down-regulate ~~[[the]]~~ said inappropriate immuno-activity of said graft by inducing cell lysis.

16. (Original) The method of claim 15 wherein the subject is a mammal.

17. (Original) The method of claim 16 wherein the mammal is a human.

18. (Original) The method of claim 15 wherein the condition is graft versus host disease.

19. (Currently amended) The method of claim 15 wherein the graft is an ~~allergenic~~allogeneic bone marrow graft, spleen cell graft or stem cell graft.

20. (Currently amended) A method for the prophylactic and/or therapeutic treatment of a condition characterized by an aberrant, unwanted or otherwise inappropriate immune response in a subject, said method comprising administering to said subject an effective amount of an antibody or antigen-binding fragment thereof which couples, binds or otherwise associates with CD83 on the surface of a myeloid DC's and/or a $CD4^+CD8^-$ T cell or $CD4^-CD8^+$ T cell, for a time and under conditions sufficient to ~~prevent~~, inhibit or otherwise down-regulate the immuno-activity of said DC and/or T cell by inducing cell lysis.

21. (New) The method of claim 12 or 15, wherein said contacting occurs *in vitro*, and thereafter returning the graft to said subject.
22. (New) The method of claim 12 or 15, wherein said contacting occurs *in vivo* in said subject.